{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:47:46Z","timestamp":1786650466432,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurol India"],"published-print":{"date-parts":[[2013]]},"DOI":"10.4103\/0028-3886.115065","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T04:47:07Z","timestamp":1373950027000},"page":"260","source":"Crossref","is-referenced-by-count":6,"title":["Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma"],"prefix":"10.4103","volume":"61","author":[{"given":"Rongjie","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0028-3886.115065-1","first-page":"2407","volume-title":"Summary statement on primary central nervous system lymphomas form the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0028-3886.115065-2","first-page":"2409","volume-title":"Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?","author":"Corn","year":"1997","journal-title":"Cancer"},{"key":"key-10.4103\/0028-3886.115065-3","first-page":"159","volume-title":"Relapse of primary central nervous system lymphoma: Clinical features, outcome and prognostic factors","author":"Jahnke","year":"2006","journal-title":"J Neurooncol"},{"key":"key-10.4103\/0028-3886.115065-4","first-page":"3743","volume-title":"Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma","author":"Raizer","year":"2012","journal-title":"Cancer"},{"key":"key-10.4103\/0028-3886.115065-5","first-page":"5034","volume-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.International Primary CNS Lymphoma Collaborative Group","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0028-3886.115065-6","first-page":"447","volume-title":"Pharmacotherapy for primary CNS lymphoma: Progress beyond methotrexate?","author":"Graber","year":"2011","journal-title":"CNS Drugs"},{"key":"key-10.4103\/0028-3886.115065-7","first-page":"666","volume-title":"Current management of primary central nervous system lymphoma","author":"Schultz","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/0028-3886.115065-8","first-page":"864","volume-title":"Temozolomide as salvage treatment in primary brain lymphomas","author":"Reni","year":"2007","journal-title":"Br J Cancer"},{"key":"key-10.4103\/0028-3886.115065-9","first-page":"139","volume-title":"Temozolomide in malignant glioma","author":"Dresemann","year":"2010","journal-title":"Onco Targets Ther"},{"key":"key-10.4103\/0028-3886.115065-10","first-page":"279","volume-title":"Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy","author":"D\u2032Incalci","year":"1988","journal-title":"Cancer Treat Rev"},{"key":"key-10.4103\/0028-3886.115065-11","first-page":"664","volume-title":"Attenuation of O (6)-methylguanine-DNA methyltransferase activity and mRNA levels by cisplatin and temozolomide in jurkat cells","author":"D\u2032Atri","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"key-10.4103\/0028-3886.115065-12","first-page":"4275","volume-title":"A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma","author":"Zustovich","year":"2009","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0028-3886.115065-13","first-page":"381","volume-title":"Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma","author":"Lombardi","year":"2011","journal-title":"J Neurooncol"},{"key":"key-10.4103\/0028-3886.115065-14","first-page":"323","volume-title":"Antitumor activity of a new platinum compound (glycolate-o, o\u2032) diammineplatinum (II) (254-S), against non-smallcell lung carcinoma grown in a human tumor clonogenic assay system","author":"Kanzawa","year":"1988","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0028-3886.115065-15","doi-asserted-by":"crossref","unstructured":"Mabuchi S, Kimura T. Nedaplatin: A radiosensitizing agent for patients with cervical cancer. Chemother Res Pract 2011;2011:963159.","DOI":"10.1155\/2011\/963159"},{"key":"key-10.4103\/0028-3886.115065-16","first-page":"69","volume-title":"Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up","author":"Omuro","year":"2005","journal-title":"Neurology"},{"key":"key-10.4103\/0028-3886.115065-17","first-page":"4643","volume-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0028-3886.115065-18","first-page":"1036","volume-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0028-3886.115065-19","first-page":"519","volume-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","author":"O\u2032Brien","year":"2000","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0028-3886.115065-20","first-page":"177","volume-title":"Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma","author":"Korfel","year":"2005","journal-title":"Br J Haematol"},{"key":"key-10.4103\/0028-3886.115065-21","first-page":"389","volume-title":"Primary CNS lymphoma in the elderly: Temozolomide therapy and MGMT status","author":"Kurzwelly","year":"2010","journal-title":"J Neurooncol"}],"container-title":["Neurology India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:18:59Z","timestamp":1786648739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.115065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"alternative-id":["115065"],"URL":"https:\/\/doi.org\/10.4103\/0028-3886.115065","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2013]]}}}